AstraZeneca drug Enhertu improves treatment response in early-stage breast cancer

AstraZeneca and Daiichi Sankyo have announced positive topline results from their Phase III DESTINY-Breast11 trial. The study found that Enhertu, followed by a taxane, Herceptin, and pertuzumab (THP) regimen, significantly improved the rate of pathologic complete response (pCR) compared to standard care in patients with high-risk, HER2-positive early-stage breast cancer.

Pathologic complete response, defined as no evidence of invasive cancer in removed breast and lymph node tissue after treatment, is a key indicator of treatment success. Achieving pCR in early-stage HER2-positive breast cancer has been associated with improved long-term outcomes.

The trial also indicated that the Enhertu plus THP combination demonstrated an improved safety profile compared to the standard of care. Standard neoadjuvant chemotherapy regimens can be associated with significant side effects, and the prospect of a better-tolerated alternative is a notable development.

Approximately one in three patients with early-stage breast cancer are considered high-risk, facing a greater likelihood of disease recurrence and poorer prognosis. The need for new treatment options that can improve outcomes for these patients remains significant.

AstraZeneca and Daiichi Sankyo intend to present the DESTINY-Breast11 data at an upcoming medical meeting and share them with regulatory authorities. Enhertu is being investigated in other breast cancer trials, including those in earlier stages of the disease.